Zymeworks Inc (ZYME)

$26.87 +0.01 (0.04%)
Market Cap 2.01B
Revenue (ttm) 76.30M
Net Income (ttm) -122.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -160.81%
Debt to Equity Ratio 0.00
Volume 241,300
Avg Vol 1,246,916
Day's Range N/A - N/A
Shares Out 74.84M
Stochastic %K 65%
Beta 1.27
Analysts Strong Sell
Price Target $35.54

Company Profile

Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform in...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 274 8744
Address:
108 Patriot Drive, Suite A, Middletown, United States
QuantumInsightCraft
QuantumInsightCraft Dec. 27 at 8:08 AM
$ZYME The backdrop favors measured delivery over aggressive expansion promises. Balance‑sheet flexibility may prove significant. Sustained improvement may validate the long‑term thesis. Momentum becomes sustainable only when delivery keeps pace.
0 · Reply
1iquid
1iquid Dec. 26 at 3:50 AM
💎 Liquid® Live Actionable Trade Asset: $ZYME Contracts: $ZYME July 17, 2026 $30 Calls Scale in: $3.52- $4.30 Scale out: $13.69-$23.48 Profit Potential : 323% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 25 at 10:14 AM
$ZYME Current Stock Price: $26.80 Contracts to trade: $25 ZYME Jan 16 2026 Call Entry: $1.00 Exit: $1.73 ROI: 73% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
maplelakeduckslayer
maplelakeduckslayer Dec. 25 at 4:54 AM
$ZYME short interest dropped to 3.9 mil shares...they don't want the smoke
1 · Reply
Lol_at_ur_bags
Lol_at_ur_bags Dec. 23 at 10:19 AM
$ZYME What do you think about $ZYME?
0 · Reply
1iquid
1iquid Dec. 22 at 4:57 AM
💎 Liquid® Live Actionable Trade Asset: $ZYME Contracts: $ZYME July 17, 2026 $30 Calls Scale in: $3.84- $4.69 Scale out: $14.92-$25.58 Profit Potential : 212% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
Lol_at_ur_bags
Lol_at_ur_bags Dec. 19 at 11:21 PM
$ZYME
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 19 at 8:47 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ZYME $25.00 Put · JAN 16, 2026 Exp Entry Price: $1.70 - $1.78 Exit Price Target: $2.63 Profit Margin: +55% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Lol_at_ur_bags
Lol_at_ur_bags Dec. 19 at 2:48 PM
$ZYME Does ZYME have medication for the problem I’m having? 👇
0 · Reply
KirRoyalTrader
KirRoyalTrader Dec. 18 at 9:57 PM
$ZYME Zymeworks looks ready for another leg higher after bouncing off the gap-up AVWAP and the 20 EMA.
0 · Reply
Latest News on ZYME
Zymeworks Inc. (ZYME) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 11:23 PM EST - 23 days ago

Zymeworks Inc. (ZYME) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Zymeworks Announces Participation in Upcoming Conferences

Dec 2, 2025, 4:05 PM EST - 24 days ago

Zymeworks Announces Participation in Upcoming Conferences

Zymeworks Announces Participation in Upcoming Investor Conferences

Nov 24, 2025, 6:00 AM EST - 4 weeks ago

Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks: Adjusting My Levels After Ziihera's Phase III Data For GEA

Nov 21, 2025, 9:11 AM EST - 5 weeks ago

Zymeworks: Adjusting My Levels After Ziihera's Phase III Data For GEA

Zymeworks: A Lot Of Moving Parts

Nov 19, 2025, 2:10 PM EST - 5 weeks ago

Zymeworks: A Lot Of Moving Parts

Zymeworks Inc. (ZYME) Shareholder/Analyst Call Transcript

Nov 18, 2025, 5:08 PM EST - 5 weeks ago

Zymeworks Inc. (ZYME) Shareholder/Analyst Call Transcript

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

Nov 18, 2025, 1:01 AM EST - 5 weeks ago

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

Nov 18, 2025, 1:00 AM EST - 5 weeks ago

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise

Nov 17, 2025, 2:43 PM EST - 5 weeks ago

Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise

JAZZ

Zymeworks Surges On Positive Ziihera Phase 3 Data: Expanding First-Line GEA Opportunity

Nov 17, 2025, 1:45 PM EST - 5 weeks ago

Zymeworks Surges On Positive Ziihera Phase 3 Data: Expanding First-Line GEA Opportunity

Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans

Nov 17, 2025, 12:09 PM EST - 5 weeks ago

Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans

JAZZ

Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.

Nov 17, 2025, 8:10 AM EST - 5 weeks ago

Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.

JAZZ

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Nov 17, 2025, 6:00 AM EST - 5 weeks ago

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Zymeworks Inc. (ZYME) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 12:06 AM EST - 7 weeks ago

Zymeworks Inc. (ZYME) Q3 2025 Earnings Call Transcript

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:05 PM EST - 7 weeks ago

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Oct 23, 2025, 12:30 PM EDT - 2 months ago

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

Oct 16, 2025, 6:00 AM EDT - 2 months ago

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

Oct 13, 2025, 4:00 PM EDT - 2 months ago

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

Oct 9, 2025, 8:30 AM EDT - 2 months ago

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

INM

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Oct 9, 2025, 6:00 AM EDT - 2 months ago

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Zymeworks: Despite T-Cell Engager Setback, ADC Candidates Press On

Sep 2, 2025, 6:09 PM EDT - 4 months ago

Zymeworks: Despite T-Cell Engager Setback, ADC Candidates Press On

Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit

Sep 2, 2025, 12:30 PM EDT - 4 months ago

Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit

Zymeworks halts development of cancer drug after trial setback

Sep 2, 2025, 6:18 AM EDT - 4 months ago

Zymeworks halts development of cancer drug after trial setback

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

Sep 2, 2025, 6:00 AM EDT - 4 months ago

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Aug 11, 2025, 6:00 AM EDT - 4 months ago

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 4:33 PM EDT - 5 months ago

Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 5 months ago

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

Jul 28, 2025, 6:00 AM EDT - 5 months ago

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Jul 17, 2025, 6:00 AM EDT - 5 months ago

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)

Jun 12, 2025, 4:34 PM EDT - 7 months ago

Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

May 30, 2025, 6:00 AM EDT - 7 months ago

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

May 22, 2025, 5:00 PM EDT - 7 months ago

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

May 19, 2025, 4:15 PM EDT - 7 months ago

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript

May 8, 2025, 11:00 PM EDT - 8 months ago

Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:05 PM EDT - 8 months ago

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline

Apr 28, 2025, 5:33 PM EDT - 8 months ago

Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline

Zymeworks: Poised For Growth With Platform Validation

Apr 28, 2025, 10:48 AM EDT - 8 months ago

Zymeworks: Poised For Growth With Platform Validation

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Apr 25, 2025, 1:00 PM EDT - 8 months ago

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

Apr 21, 2025, 6:00 AM EDT - 8 months ago

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Apr 17, 2025, 6:00 AM EDT - 9 months ago

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 9 months ago

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251

Mar 6, 2025, 1:18 PM EST - 10 months ago

Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251

Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 8:43 PM EST - 10 months ago

Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 4:05 PM EST - 10 months ago

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

Feb 26, 2025, 6:00 AM EST - 10 months ago

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

Feb 18, 2025, 6:00 AM EST - 11 months ago

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

Feb 13, 2025, 6:00 AM EST - 11 months ago

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

3 Biotech Stocks With Notable Insider Buying

Jan 22, 2025, 12:29 PM EST - 1 year ago

3 Biotech Stocks With Notable Insider Buying

AUPH AZN COGT JAZZ ONC XBI

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Jan 8, 2025, 4:05 PM EST - 1 year ago

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule

Dec 19, 2024, 9:00 AM EST - 1 year ago

Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule

QuantumInsightCraft
QuantumInsightCraft Dec. 27 at 8:08 AM
$ZYME The backdrop favors measured delivery over aggressive expansion promises. Balance‑sheet flexibility may prove significant. Sustained improvement may validate the long‑term thesis. Momentum becomes sustainable only when delivery keeps pace.
0 · Reply
1iquid
1iquid Dec. 26 at 3:50 AM
💎 Liquid® Live Actionable Trade Asset: $ZYME Contracts: $ZYME July 17, 2026 $30 Calls Scale in: $3.52- $4.30 Scale out: $13.69-$23.48 Profit Potential : 323% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 25 at 10:14 AM
$ZYME Current Stock Price: $26.80 Contracts to trade: $25 ZYME Jan 16 2026 Call Entry: $1.00 Exit: $1.73 ROI: 73% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
maplelakeduckslayer
maplelakeduckslayer Dec. 25 at 4:54 AM
$ZYME short interest dropped to 3.9 mil shares...they don't want the smoke
1 · Reply
Lol_at_ur_bags
Lol_at_ur_bags Dec. 23 at 10:19 AM
$ZYME What do you think about $ZYME?
0 · Reply
1iquid
1iquid Dec. 22 at 4:57 AM
💎 Liquid® Live Actionable Trade Asset: $ZYME Contracts: $ZYME July 17, 2026 $30 Calls Scale in: $3.84- $4.69 Scale out: $14.92-$25.58 Profit Potential : 212% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
Lol_at_ur_bags
Lol_at_ur_bags Dec. 19 at 11:21 PM
$ZYME
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 19 at 8:47 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ZYME $25.00 Put · JAN 16, 2026 Exp Entry Price: $1.70 - $1.78 Exit Price Target: $2.63 Profit Margin: +55% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Lol_at_ur_bags
Lol_at_ur_bags Dec. 19 at 2:48 PM
$ZYME Does ZYME have medication for the problem I’m having? 👇
0 · Reply
KirRoyalTrader
KirRoyalTrader Dec. 18 at 9:57 PM
$ZYME Zymeworks looks ready for another leg higher after bouncing off the gap-up AVWAP and the 20 EMA.
0 · Reply
JarvisFlow
JarvisFlow Dec. 17 at 3:05 PM
Truist Securities has adjusted their stance on Zymeworks ( $ZYME ), setting the rating to Buy with a target price of 40.
0 · Reply
maplelakeduckslayer
maplelakeduckslayer Dec. 17 at 12:06 PM
$ZYME Truist upgrades to buy with $40 pt. Avg analyst target 35.54 now
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 16 at 8:42 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ZYME $25.00 Put · JAN 16, 2026 Exp Entry Price: $1.85 - $2.05 Exit Price Target: $4.49 Profit Margin: +119% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
trading_momentum_x
trading_momentum_x Dec. 16 at 12:19 PM
$ZYME Holding up well above support at 25.886 with a steady grind into 26.13 close. Cluster resistance sits tight between 25.977 and the 26.13 area. If bulls can flip 26.13 and hold, this could tag 26.30 and potentially 26.50. Support zones at 25.886 then 25.70. Trend looks constructive as long as it stays above the lower support for now.
0 · Reply
trading_momentum_x
trading_momentum_x Dec. 16 at 12:17 PM
$ZYME (Zymeworks Inc.) Technical setup: RSI mid-50s, MACD positive, price holding near 1-hr 20 SMA; recent Wells Fargo upgrade provides tail-wind. Momentum: Gradual accumulation since late-Nov breakout from $23 base; higher lows visible on intraday structure. Outlook: Bias remains bullish toward $27–$28 resistance; failure to hold $25.5 could neutralize momentum short-term.
0 · Reply
trading_momentum_x
trading_momentum_x Dec. 16 at 12:15 PM
$ZYME - still above the 20 DMA, and a retest of 25.3 - we could be going higher. Top BB would be the target at 28 with a S/L at 25.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 12 at 9:52 PM
$ZYME Current Stock Price: $25.50 Contracts to trade: $25 ZYME Dec 19 2025 Call Entry: $3.15 Exit: $5.85 ROI: 86% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
DARKP00L
DARKP00L Dec. 12 at 4:32 PM
$ZYME 11:29 on Dec. 12 2025 Wells Fargo Upgrades Zymeworks to Overweight, Raises Price Target to $33 #tradeideas
0 · Reply
JarvisFlow
JarvisFlow Dec. 12 at 4:29 PM
Wells Fargo has adjusted their stance on Zymeworks ( $ZYME ), setting the rating to Overweight with a target price of 25 → 33.
0 · Reply
notreload_ai
notreload_ai Dec. 12 at 1:52 PM
Wells Fargo upgrades $RLAY and $ZYME , raising price targets and highlighting potential 2026 growth from clinical data and cancer treatment opportunities. https://notreload.xyz/wells-fargo-upgrades-relay-therapeutics-and-zymeworks-stocks/
0 · Reply
trading_momentum_x
trading_momentum_x Dec. 12 at 11:18 AM
$ZYME - wow, a stock that's not completely terrible. A break out higher causing a gap however about to lose the 20 DMA at 24.8. We lose that, a gap close at 20 is possible.
1 · Reply
BuyingSheep
BuyingSheep Dec. 11 at 9:32 PM
$ZYME it‘s coming ….
0 · Reply